CD8-positive T-cell
A CD8-positive T-cell (CD8⁺ T cell) is a T-lymphocyte that expresses the CD8 co-receptor, usually as a CD8αβ heterodimer.
A CD8-positive T-cell (CD8⁺ T cell) is a T-lymphocyte that expresses the CD8 co-receptor, usually as a CD8αβ heterodimer. CD8 strengthens interactions between the T-cell receptor and peptide–major histocompatibility complex class I (MHC I) molecules displayed by nucleated cells. Following antigen recognition and appropriate co-stimulation, CD8⁺ T cells can differentiate into cytotoxic effector cells, memory T cells, or dysfunctional/exhausted states. Effector CD8⁺ T cells eliminate infected or transformed cells through cytotoxic granules and death-receptor pathways and can produce cytokines such as Interferon gamma and Tumor necrosis factor-α (TNF-α)-α.
CD8⁺ T cells are central components of antiviral and antitumor immunity. Their activity is shaped by antigen-presenting cells, particularly dendritic cells capable of cross-priming, as well as by the tumor microenvironment, regulatory T cells, Macrophages, transforming growth factor, metabolic conditions, and immune-checkpoint pathways. In Cancer, CD8⁺ T cells may recognize tumor-associated or tumor-specific antigens, but their function can be limited by inhibitory receptors such as LAG3 and TIGIT, suppressive Signaling involving CD274 molecule (PD-L1), nutrient competition, and lactate accumulation. These properties make CD8⁺ T cells important targets and effectors of immunotherapy, including adoptive tumor-infiltrating lymphocyte (TIL) Therapy, checkpoint inhibitor treatment, cytokine-based agents, and approaches designed to improve dendritic-cell priming.
Rebuilt from PubMed 18 Sept 2026 · no new papers today
Where the papers sit
11 papers study cd8-positive t-cell directly. The themes below are drawn from those 11. 1 paradigm shift and 1 new direction follow.
-
CD8 T-Cell States : Exhaustion and tissue context dominate CD8+ T-cell biology, with PD-1/LAG-3 states, cuproptosis, and LOXL4-driven matrix stiffening linked to immunotherapy response. Single-cell profiling also tracks CX3CR1+ clones in anti-NMDA receptor encephalitis. 4 papers · 36.4%
-
Tumor-Reactive T-Cell Therapy : Tumor-reactive CD8+ T cells are being selected and functionally reprogrammed to improve immunotherapy. TIL phenotypes predict outcome, while TIGIT-targeted IL-12 and TGR5-dependent dendritic-cell cross-priming counter exhaustion and strengthen antitumor responses. 4 papers · 36.4%
-
Tumor Immunotherapy Delivery : Targeted delivery and local immune conditioning are being used to restore antigen presentation and improve CD8+ T-cell killing. AAV administration can itself activate CD8+ T cells, while muscle promoter specificity and Cofilin1-driven remodeling shape responses. 3 papers · 27.3%
CD8-positive T cells can create, rather than merely exploit, tumor-cell susceptibility to therapy
The medulloblastoma model studied by the local-interferon delivery paper and the cuproptosis-immunity systems studied by the cuproptosis paper both replace the usual one-way picture in which CD8-positive T cells act only as downstream killers of tumor cells. In medulloblastoma, CD8-derived IFN-γ restores tumor-cell MHC class I and thereby enables T-cell killing; in cuproptosis models, the same cytokine induces tumor-cell FDX1 and increases sensitivity to cuproptosis, while cuproptotic death further stimulates antitumor immunity 42735303Sep 42330950Jun. The resulting change is conceptual as well as therapeutic: CD8-positive T-cell activity is itself a mechanism for remodeling tumor vulnerability and can determine whether otherwise ineffective tumor-directed treatments work.
CD8-positive T cells are identified as clonally expanded pathogenic effectors in anti-NMDA receptor encephalitis
The anti-NMDA receptor encephalitis study uses single-cell transcriptomic, T-cell-receptor and epitope profiling to assign CD8-positive T cells a disease-driving role outside the set's dominant tumor-immunity and therapeutic-response frameworks. It identifies clonally expanded CX3CR1-expressing CD8-positive T cells in cerebrospinal fluid as disease-associated effectors with predicted GluN1-epitope reactivity, cytotoxic and proinflammatory programs, and interaction with activated B cells, rather than treating them as incidental immune participants 42711907Sep. This redirects attention toward CD8-positive T cells as potential mediators of autoimmune neuroinflammation and therapeutic resistance in anti-NMDA receptor encephalitis.
Recent Findings on CD8-positive T-cell
T-Cell Exhaustion and Immunity: Intratumoral PD-1+LAG-3+CD8+ T cells mark a tumor-reactive, pre-exhausted state associated with improved prognosis and pembrolizumab response in gastric cancer 42742874Sep. Lung-cancer models instead connect LOXL4-driven matrix stiffening to Piezo1, FAK1-YAP1, and epigenetically reinforced terminal exhaustion; acetyldigoxin reversed this process and enhanced anti-PD-1 therapy 42726857Sep. Anti-N-methyl-D-aspartate receptor encephalitis shows that clonally expanded CX3CR1+ CD8+ T cells can sustain pathogenic inflammation through cytotoxic programs and elevated interferon-γ and tumor necrosis factor-α production 42711907Sep. Cuproptosis studies further link CD8+ T-cell-derived interferon-γ to tumor FDX1 induction, suggesting that cuproptosis inducers plus anti-PD-L1 therapy can overcome resistance 42330950Jun.
Tumor-Reactive T-Cell Therapy: Tumor-reactive LAG3+CD8+ T-cell clonotypes follow divergent fates, with LAG3+ cells becoming terminally exhausted while LAG3− progenitors support durable memory responses 42611047Aug. In advanced melanoma, infused CD8+TCRαβ+ T-cell number, tumor reactivity, and peripheral persistence predicted response and progression-free survival after TIL therapy 42149143May. Chenodeoxycholic acid strengthened the TGR5-dependent cDC1–CD8+ T-cell axis and synergized with anti-PD-1 therapy and poly I:C in mouse tumors 42503514Jul. The αTIGIT-IL12 fusion protein similarly concentrated IL-12 activity within tumors, activated intratumoral NK and CD8+ T cells, and improved efficacy and tolerability compared with wild-type IL-12 42302794Jun.
T-Cell Immunotherapy Delivery: Local interferon gamma delivery restored MHC class I expression and sensitized medulloblastoma cells to tumor-reactive CD8+ T-cell killing, prolonging survival in mice 42735303Sep. Constitutively active CFL1 increased F-actin bundling, immunological synapse formation, and tumor vulnerability, while AAV delivery with PD-1 blockade nearly eradicated tumors across models 42586064Aug. AAV studies show that draining lymph nodes present transgene-derived peptides within one day, and muscle-promoter design determines early dendritic-cell expression and cytotoxic CD8+ T-cell activation 42262864Jun.
Written from 11 PubMed abstracts, each one cited by PMID above. Published: 2026-08-20. Last written: 2026-09-17 by GPT. Drafted by language models from published abstracts; not medical advice.